Details of the Drug Combination

General Information of Drug Combination (ID: DC1NA56)

• Drug Combination Name: BIO-300 + Arfolitixorin
• Indication: Papillary renal cell carcinoma; Status: Investigative [1]
• Component Drugs:
  BIO-300 (DMJ7NVI): N.A.
  Arfolitixorin (DMIXMYK): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: ACHN
  Zero Interaction Potency (ZIP) Score: 3.09
  Bliss Independence Score: 3.42
  Loewe Additivity Score: 3.34
  LHighest Single Agent (HSA) Score: 7.22

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult acute myeloid leukemia	DCMPTLK	HL-60(TB)	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCO6IUI	MOLT-4	Investigative	[1]
Anaplastic large cell lymphoma	DCALE5O	SR	Investigative	[1]
Glioma	DCMHNI8	SF-268	Investigative	[1]
Colon adenocarcinoma	DC1L7KJ	COLO 205	Investigative	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of Humanetics.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
• [5] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.